Aravive, Inc. to Delist from The Nasdaq Stock Market
17. Januar 2024 16:09 ET
|
Aravive, Inc.
HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the...
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
02. August 2023 16:01 ET
|
Aravive, Inc.
Trial did not meet primary endpoint of progression-free survivalCash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON,...
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
28. Juli 2023 07:05 ET
|
Aravive, Inc.
HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
14. Juli 2023 07:05 ET
|
Aravive, Inc.
HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today...
Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
13. Juni 2023 16:05 ET
|
Aravive, Inc.
HOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive To Participate in the Jefferies Global Healthcare Conference
05. Juni 2023 16:05 ET
|
Aravive, Inc.
HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today...
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
25. Mai 2023 17:00 ET
|
Aravive, Inc.
HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
16. Mai 2023 07:05 ET
|
Aravive, Inc.
Trial initiation anticipated in 2H 2023 with topline data anticipated in 2H 2025Updated Phase 1b/2 ccRCC data to be presented at ASCO 2023 HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc....
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
10. Mai 2023 16:05 ET
|
Aravive, Inc.
On Track for PROC Pivotal Phase 3 Trial Readout Mid-2023Promising ccRCC Phase 1b/2 Results to Date; Update to be Presented at ASCO 2023Strengthened Management Team with Appointment of Carolina Petrini...
Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
08. Mai 2023 07:05 ET
|
Aravive, Inc.
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...